Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

British Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 69-74

  Alexopoulos, C G ^a   Vaslamatzis, M ^a   Hatzidimitriou, G ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Cancer chemotherapy; HBsAg carriers; HBV profile

Indexed keywords

ANTINEOPLASTIC AGENT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR; VIREMIA; VIRUS CARRIER; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARRIER STATE; FEMALE; FOLLOW-UP STUDIES; GREECE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; VIRUS ACTIVATION;

EID: 0032858026     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690652     Document Type: Article

References (12)

1. Alexopoulos CG, Vaslamatzis M, Zoublios C and Chatzidimitriou G (1992) Reactivation of hepatitis B in HBsAg carriers during cancer chemotherapy. Ann Oncol 3: 65
2. Alexopoulos CG, Vaslamatzis M and Chatzidimitriou G (1997) Incidence of hepatitis B virus (HBV) positivity and behaviour of hepatitis B surface antigen (HBsAg) carrier state in cancer patients, during chemotherapy (CT). Proc Am Soc Clin Oncol 16: A1490
3. Bird GLA, Smith H, Ponmann B, Alexander GJM and Williams R (1989) Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Quart J Med, New Series 73 270: 895-902
4. Gallbraith RM, Eddleston AL, Williams R, Zucherman AJ and Bagshaw KD (1975) Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2: 528-530
5. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich CK, Young CR and Costa J (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Am Intern Med 96: 447-449
6. Lau JYN, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu CP, Chan KT and Todd D (1989) Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Quart J Med New Series 73 270: 911-917
7. Nakamura Y, Motokura T, Fujita A, Yamashita T and Ogata E (1996) Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan 1987 1991. Cancer 78: 2210-2215
8. Ngan R, Tung S, Lau WH and Lam J (1995) Lung term results of aggressive lymphoma using PROMACE-CYTABOM. peculiar patient group and toxicity. Proc Am Soc Clin Oncol 14: 1251
9. Ohtsu T, Sai T, Oka M, Shgai Y and Tobinai K (1991) Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 21: 360-365
10. Pinto CP, Hu E, Bernstein-Singer M, Pinter-Brown L and Govindarajans (1990) Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65: 878-884
11. Scullard GH, Smith CI, Merigan TC, Robinson WS and Gregory PB (1981) Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81: 987-991
12. Wands JR, Chura CM, Roll FJ and Maddrey WC (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68: 105-112